Bessemer Group
PGNX

Bessemer Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bessemer Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-344
Closed -$2K – 1517
2016
Q1 		$2K Buy
+344
New +$1.53K ﹤0.01% 1409

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's PGNX Position: Q2 2016 in Review

Bessemer Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2016, closing a stake of 344 shares — an estimated $2K sold.

Bessemer Group first reported a position in PGNX in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 104 funds tracked by Wall St. Rank hold PGNX as of Q2 2016.

  • Bessemer Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 344 Progenics Pharmaceuticals Inc shares in Q2 2016, an estimated $2K.
  • Bessemer Group first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • Bessemer Group's Progenics Pharmaceuticals Inc position peaked at $2K in Q1 2016.
  • 104 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.